<DOC>
	<DOCNO>NCT02273401</DOCNO>
	<brief_summary>To investigate safety , tolerability , pharmacokinetics BI 11054</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Single Rising Inhaled Doses BI 11054 CL Administered With Respimat® Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male base upon complete medical history , include physical examination , regard vital sign ( BP , PR ) , 12lead ECG measurement , clinical laboratory test . There find deviate normal clinical relevance . There evidence clinically relevant concomitant disease . Age ≥21 ≤50 year Body mass index ( BMI ) ≥18.5 &lt; 30 kg/m2 Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Any finding medical examination ( include BP , PR , ECG measurement ) deviate normal clinical relevance Evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) judge clinically relevant investigator Intake drug long halflife ( &gt; 24 hour ) within least 1 month less 10 halflives respective drug prior randomisation Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior randomisation Participation another trial investigational drug within 2 month prior randomisation Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day judge investigator Alcohol abuse ( 40 g alcohol day ) Drug abuse Blood donation ( 100 mL blood within 4 week prior randomisation trial ) Excessive physical activity within 1 week prior randomisation trial Any laboratory value outside reference range clinical relevance Inability comply dietary regimen study centre The following exclusion criterion specific study due know class side effect profile ß2mimetics : Asthma history pulmonary hyperreactivity Hyperthyrosis Allergic rhinitis need treatment Clinically relevant cardiac arrhythmia Paroxysmal tachycardia ( &gt; 100 beat per minute )</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>